Suwanpradid Jutamas, Shih Michael, Pontius Lauren, Yang Bin, Birukova Anastasiya, Guttman-Yassky Emma, Corcoran David L, Que Loretta G, Tighe Robert M, MacLeod Amanda S
Department of Dermatology, Duke University, Durham, NC 27710.
Department of Medicine, Duke University, Durham, NC 27710.
J Immunol. 2017 Sep 1;199(5):1827-1834. doi: 10.4049/jimmunol.1700739. Epub 2017 Jul 26.
The innate immune components that modulate allergic contact hypersensitivity (CHS) responses are poorly defined. Using human skin from contact dermatitis patients and a mouse model of CHS, we find that hapten allergens disrupt the Arginase1 (Arg1) and inducible NO synthase (iNOS) dynamic in monocytes/macrophages (mono/MΦ), which renders those cells ineffectual in suppressing skin inflammation. Mice lacking Arg1 in MΦ develop increased CHS characterized by elevated ear thickening, mono/MΦ-dominated dermal inflammation, and increased iNOS and IL-6 expression compared with control mice. Treatment of Arg1; LysMCre mice with a selective NOS inhibitor or knockout of , encoding iNOS, significantly ameliorates CHS. Our findings suggest a critical role for Arg1 in mono/MΦ in suppressing CHS through dampening expression. These results support that increasing Arg1 may be a potential therapeutic avenue in treating allergic contact dermatitis.
调节过敏性接触超敏反应(CHS)的先天性免疫成分尚不清楚。利用接触性皮炎患者的人类皮肤和CHS小鼠模型,我们发现半抗原过敏原破坏了单核细胞/巨噬细胞(mono/MΦ)中精氨酸酶1(Arg1)和诱导型一氧化氮合酶(iNOS)的动态变化,这使得这些细胞在抑制皮肤炎症方面无效。与对照小鼠相比,MΦ中缺乏Arg1的小鼠CHS增加,其特征是耳部增厚加剧、以mono/MΦ为主的皮肤炎症以及iNOS和IL-6表达增加。用选择性NOS抑制剂治疗Arg1;LysMCre小鼠或敲除编码iNOS的基因,可显著改善CHS。我们的研究结果表明,Arg1在mono/MΦ中通过抑制 表达在抑制CHS中起关键作用。这些结果支持增加Arg1可能是治疗过敏性接触性皮炎的潜在治疗途径。